Physician profile

Daniel Su

Urology · Laguna Hills, CA

NPI 1235442534

$38,862.34

in general payments reported to CMS, 2019-2025

41 companies · $23K in 2025

The $23K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$16,568.75
Food and Beverage$6,823.86
Travel and Lodging$5,535.76
Education$4,519.31
Consulting Fee$825.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Teleflex LLC $20,476.54 2020-2025 Barrigel, Urolift
Intuitive Surgical, INC. $5,582.23 2020-2023 Da Vinci Sp, Da Vinci Surgical System
Procept Biorobotics Corporation $2,780.65 2024-2025 Aquabeam System
Histosonics, INC. $1,651.63 2024-2025
Profound Medical Corp. $1,336.68 2024-2025 Tulsa-Pro
Abbvie INC. $1,125.85 2019-2025 Lupron Depot, Alloderm, Botox
Janssen Biotech, INC. $870.16 2021-2025 Erleada, Akeega, Balversa
Astellas Pharma US INC $512.41 2019-2025 Xtandi, Myrbetriq
Uromedica, Incorporated $452.50 2019
Bayer Healthcare Pharmaceuticals INC. $373.47 2021-2025
Genentech USA, INC. $263.31 2023-2025 Vabysmo
Pfizer INC. $254.02 2019-2025
Astrazeneca Pharmaceuticals Lp $247.21 2023-2024 Lynparza
Merck Sharp & Dohme LLC $241.49 2022-2025 Keytruda, Lynparza, Welireg
Myovant Sciences INC. $241.21 2021-2022
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Medtronic, INC. $226.35 2025 Interstim
Axonics, INC. $199.60 2021-2022
Accord Healthcare, INC. $184.53 2023-2025
Urogen Pharma, INC. $173.90 2022-2023 Jelmyto
Palette Life Sciences, INC. $166.46 2022-2023
Edap Technomed INC $146.42 2023
Dendreon Pharmaceuticals LLC $139.41 2019-2025 Provenge
Sumitomo Pharma America, INC. $138.57 2023-2025 Gemtesa
Progenics Pharmaceuticals, INC. $137.84 2021-2025
Boehringer Ingelheim Pharmaceuticals, INC. $122.21 2021
Cook Medical LLC $91.91 2023 Fiber Dust
Tempus Ai, INC $87.60 2024 Xt Cdx
Antares Pharma, INC. $77.58 2021
Novartis Pharmaceuticals Corporation $76.97 2022-2025
Telix Pharmaceuticals $73.58 2023-2025 Illuccix
Blue Earth Diagnostics $61.23 2024-2025 Posluma
Neotract INC. $57.93 2019-2020
Boston Scientific Corporation $56.67 2025 Spaceoar System
Urovant Sciences INC $51.42 2021-2022
Allergan, INC. $43.68 2019
Bioprotect Medical, INC. $38.89 2024 Bioprotect Balloon Implant System
Tolmar, INC. $23.65 2023
Ferring Pharmaceuticals INC. $23.01 2024 Adstiladrin
Olympus America INC. $20.85 2025 Bovie
Calyxo, INC. $16.67 2025 Cvac Aspiration System
Foundation Medicine, INC. $16.05 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Su

$38,862.34

in general payments reported 2019-2025

Years
2019-2025
Top company
Teleflex LLC
Context
The $23K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/683574/daniel-su

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.